ArticleCardiology research and practice2026
Routine CYP2C19 Genotyping, Antiplatelet Prescription Changes, and Clinical Outcomes After PCI in Chinese Patients With Coronary Heart Disease: A Single-Center Retrospective Study.
Article in Cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CYP2C19 genotype can influence clopidogrel response, but the relationship between routine genotyping, real-world P2Y12 inhibitor prescribing, and clinical outcomes remains uncertain. Aims: To characterize P2Y12 inhibitor prescription patterns before and after routine CYP2C19 genotyping and to describe ischemic and bleeding outcomes in a retrospective real-world cohort. Methods: This single-center retrospective study included 364 adults with coronary heart disease who underwent percutaneous coronary intervention (PCI) from January to December 2023. During the study period, CYP2C19 genotyping was routinely performed as part of the hospital's antiplatelet management policy, and all 364 participants were genotyped. Prescription patterns before and after genotype results were compared; clinical outcome analyses were restricted to the 271 patients with complete linked postdischarge medication and outcome data. Results: Before genotyping, 273/364 patients (75.0%) received ticagrelor, and 91/364 (25.0%) received clopidogrel; after genotype results, 279/364 (76.6%) received clopidogrel, and 85/364 (23.4%) received ticagrelor. From the reported adjustment counts, 258 patients switched from ticagrelor to clopidogrel, 70 switched from clopidogrel to ticagrelor, and 36 remained on the same agent (exact McNemar Conclusions: Routine CYP2C19 genotyping was associated with a substantial change in P2Y12 inhibitor prescribing in this single-center cohort. Because treatment was physician-directed and outcome data were sparse and incomplete for the full cohort, the clinical event comparisons should be interpreted as exploratory rather than evidence that genotype-guided therapy reduced bleeding or ischemic events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.